Print

OrbusNeich Announces Availability of Azule(TM) Cobalt Chromium Stent  
3/14/2011 7:09:04 AM

HONG KONG, March 14, 2011 /PRNewswire/ -- OrbusNeich today announced the launch of the CE marked Azule Cobalt Chromium Stent. The Azule Stent combines the proven stent design of its predecessor, the company's Blazer Cobalt Chromium Stent, with a delivery system with enhanced crossability and flexible deliverability.

Azule features OrbusNeich's unique Dual Helix stent design, offering conformability and radial strength on thin, flexible and low-profile cobalt chromium stent struts. The stent's tip length has been reduced from 5 mm to 4.25 mm, improving deliverability and crossability. The precise laser forming of the tip results in a lower lesion entry profile, and the controlled laser welding of the balloon to the catheter improves the stent's trackability and flexibility.

"Continuous technology advancement is mandated by our customers and the very nature of interventional cardiology," said Al Novak, OrbusNeich's Chairman and CEO. "We believe the underlying deliverability of a stent is, and will continue to be, a critically important factor that we strive to improve."

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule, R stent, Scoreflex, Sapphire, Sapphire II and Sapphire NC. Development stage products include the Combo Bio-engineered Sirolimus Eluting Stent, or Combo Stent, which combines the Genous pro-healing technology for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com. Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich.

SOURCE OrbusNeich


//-->